Navigation Links
Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study

By Steven Reinberg
HealthDay Reporter

THURSDAY, March 24 (HealthDay News) -- Just six months of hormone therapy, along with radiation, cuts the risk of dying from locally advanced prostate cancer in half when compared to radiation alone, researchers report.

Just as important, the study indicates that a short course of hormone therapy has few of the side effects seen with longer treatment regimens of two to three years.

Hormone therapy in men, also known as androgen-deprivation therapy, lowers levels of the male hormones that encourage prostate cancer to grow.

"A halving of the risk of dying from these more advanced prostate cancers clearly has very major significance for men affected," said researcher Dr. David Lamb, director of the Prostate Cancer Trials Unit at the University of Otago in Wellington, New Zealand.

"Early diagnosis of prostate cancer remains the goal, but at least men presenting with more advanced tumors can now be offered treatment proven to have a much better chance of cure," he said.

The report is published in the March 24 online edition of The Lancet Oncology.

As part of the Trans-Tasman Radiation Oncology Group trial, Lamb's group randomly assigned 802 men with locally advanced prostate cancer to radiation alone, or three months of hormone therapy plus radiation, or six months of hormone therapy and radiation.

Over an average of 10.6 years of follow-up, men who received six months of hormone therapy and radiation were significantly less likely to die from prostate cancer than men who had radiation alone -- 11 percent vs. 22 percent, respectively. They were also much less likely to die from any cause -- 29 percent vs. 43 percent, the researchers found.

Hormone therapy over three months had no effect on the spread of prostate cancer, or dying from the cancer or any other cause, compared with radiation alone, Lamb's team noted.

Compared to a six-month bout of the hormone therapy, androgen-deprivation therapy over an extended period can result in serious side effects, including erectile dysfunction, hot flashes, fatigue, osteoporosis, high cholesterol, anemia and cardiac death.

"This study with locally advanced prostate cancers has shown that adding [just] six months of hormone treatment to radiotherapy halves the numbers of deaths from prostate cancer in the next 10 years," Lamb said.

"Whilst there were already known to be benefits from short-term hormone treatment in this group of patients, this is the first trial to demonstrate the magnitude of long-term benefits. A 50 percent improvement in survival is a massive gain, and it was achieved with relatively few extra side effects for patients," he added.

Prostate cancer expert Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said this study validates his own research, which showed that six months of hormone therapy plus radiation prolonged survival.

"You get an overall survival benefit when you add six months of hormone therapy to radiation in men with high-risk prostate cancer," he said. "Six months of hormonal therapy with radiation is a valid treatment option with high-risk prostate cancer."

Men may choose to have longer hormone treatment, D'Amico said. However, survival will probably only marginally improve, and there is a risk for heart problems with the prolonged use of hormone therapy, he said.

More information

For more information on prostate cancer, visit the American Cancer Society.

SOURCES: David Lamb, M.B., F.R.C.P., director, Prostate Cancer Trials Unit, University of Otago, Wellington, New Zealand; Anthony D'Amico, M.D., Ph.D, chief, radiation oncology, Brigham and Women's Hospital, Boston; March 24, 2011, The Lancet Oncology, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
2. For Some Breast Cancer Patients, Shorter Radiation Works Well
3. Short-term radiation therapy successful on breast cancer
4. No End In Sight To The Armour Thyroid Shortage?
5. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
6. Americans Falling Short on Heart-Healthy Fruits and Vegetables
7. Website for Nursing Jobs Launches -- Streamlined Job Board Created to Address Nursing Shortage
8. Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services
9. Newer cornea transplant surgery shows short- and long-term promise
10. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
11. Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath
Post Your Comments:
Related Image:
Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... , ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - ... CES 2016, the world’s largest Consumer Electronic Show, where they will present to a ... of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top ...
(Date:12/1/2015)... ... 2015 , ... SonaCare Medical congratulates the University College London ... on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative ... medical landscape. , The UCLH team won the award for their innovative approach ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology: